GSK and iTeos Therapeutics have discontinued development of belrestotug, their TIGIT-targeting immunotherapy, after it failed to significantly delay tumor progression in non-small cell lung cancer patients.
iTeos Therapeutics is set to release multiple TIGIT clinical data readouts throughout 2025, involving over 400 patients from Phase 2 and Phase 1/2 trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.